Drug · CHEMBL3545252

DOCETAXEL

7 sourcespipelines-2026-09-18-0.3.1

Cite this record

ConductScience Library. DOCETAXEL. Drugs and targets, record CHEMBL3545252. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL3545252

On this page

Drug

Names and IDs as ChEMBL gives them, through Open Targets.

Name: DOCETAXEL; ChEMBL
ChEMBL ID: CHEMBL3545252; ChEMBL
Type: Small molecule; ChEMBL
Brand names: Beizray, Docetaxel accord, Docetaxel teva, Docetaxel zentiva (previously docetaxel winthrop), Docivyx, Taxceus, Taxespira (previously docetaxel hospira uk limited ), Taxotere; ChEMBL
Other names: Docetaxel (as trihydrate), Docetaxel hydrate, Docetaxel trihydrate, RP 56976, RP-56976, XRP6976; ChEMBL
Parent form: DOCETAXEL ANHYDROUS, CHEMBL92; Drugs and targets
InChIKey: XCDIRYDKECHIPE-QHEQPUDQSA-N; ChEMBL
Open Targets' highest stage: Approval, for 10 of its 171 diseases, from ATC, DailyMed and EMA Human Drugs; Open Targets

Targets15

The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.

Target	Protein	Mechanism	Action	Gene in Genes
TUBA1A	Tubulin	Tubulin inhibitor	INHIBITOR	https://conductscience.org/library/genes/7846
TUBA1B	Tubulin	Tubulin inhibitor	INHIBITOR	https://conductscience.org/library/genes/10376
TUBA1C	Tubulin	Tubulin inhibitor	INHIBITOR	https://conductscience.org/library/genes/84790
TUBA3C	Tubulin	Tubulin inhibitor	INHIBITOR	https://conductscience.org/library/genes/7278
TUBA3E	Tubulin	Tubulin inhibitor	INHIBITOR	https://conductscience.org/library/genes/112714
TUBA4A	Tubulin	Tubulin inhibitor	INHIBITOR	https://conductscience.org/library/genes/7277
TUBB	Tubulin	Tubulin inhibitor	INHIBITOR	https://conductscience.org/library/genes/203068
TUBB1	Tubulin	Tubulin inhibitor	INHIBITOR	https://conductscience.org/library/genes/81027
TUBB2A	Tubulin	Tubulin inhibitor	INHIBITOR	https://conductscience.org/library/genes/7280
TUBB2B	Tubulin	Tubulin inhibitor	INHIBITOR	https://conductscience.org/library/genes/347733

1 to 10 of 15Source ChEMBL

See all 15 targets

Diseases171

The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Disease	Open Targets' stage	Stage reported by	Reports	Of them trials	Its drugs
breast cancer	Approval	DailyMed	486	484	https://conductscience.org/library/drugs?q=MONDO_0007254
non-small cell lung carcinoma	Approval	DailyMed and EMA Human Drugs	503	481	https://conductscience.org/library/drugs?q=MONDO_0005233
prostate cancer	Phase 3	ClinicalTrials.gov	324	324	https://conductscience.org/library/drugs?q=MONDO_0008315
gastric cancer	Phase 3	ClinicalTrials.gov	115	115	https://conductscience.org/library/drugs?q=MONDO_0001056
head and neck squamous cell carcinoma	Phase 3	ClinicalTrials.gov	106	106	https://conductscience.org/library/drugs?q=MONDO_0010150
gastric adenocarcinoma	Phase 3	ClinicalTrials.gov	81	81	https://conductscience.org/library/drugs?q=MONDO_0005036
gastroesophageal junction adenocarcinoma	Phase 3	ClinicalTrials.gov	62	62	https://conductscience.org/library/drugs?q=MONDO_0003219
nasopharyngeal carcinoma	Phase 3	ClinicalTrials.gov	53	53	https://conductscience.org/library/drugs?q=MONDO_0015459
esophageal cancer	Phase 3	ClinicalTrials.gov	35	35	https://conductscience.org/library/drugs?q=MONDO_0007576
cancer	Phase 3	ClinicalTrials.gov	31	31	https://conductscience.org/library/drugs?q=MONDO_0004992

1 to 10 of 171Source Open Targets

See all 171 diseases

Trials2,251

Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs. 2 more rest on that reading alone and are shown because the trials' posted result groups or NLM's indexing of their papers name the drug. 21 more that Open Targets linked to it are not shown, since the release's checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Named as	Linked by	Source
NCT00003782	Combination Chemotherapy in Treating Women With Stage I, Stage II, or Stage IIIA (cT1-3, N0-1, M0) Breast Cancer and Positive Axillary Lymph Nodes	Phase 3	5,351	2012-10-31	docetaxel	Its name	ClinicalTrials.gov
NCT00093795	Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Positive Breast Cancer	Phase 3	4,894	2017-12-12	docetaxel	Its name	ClinicalTrials.gov
NCT01358877	A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer	Phase 3	4,804	2018-01-05	docetaxel	Its name	ClinicalTrials.gov
NCT00312208	Docetaxel in Breast Cancer	Phase 3	3,299	2010-02-17	docetaxel	Its name	ClinicalTrials.gov
NCT01275677	Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer	Phase 3	3,270	2020-09-23	docetaxel	Its name	ClinicalTrials.gov
NCT00021255	Combination Chemotherapy With or Without Trastuzumab in Treating Women With Breast Cancer	Phase 3	3,222	2016-11-15	docetaxel	Its name	ClinicalTrials.gov
NCT00089479	A Study of Xeloda (Capecitabine) in Women With High-Risk Breast Cancer	Phase 3	2,611	2011-06-23	docetaxel	Its name	ClinicalTrials.gov
NCT00493870	TAC Versus TC for Adjuvant Breast Cancer	Phase 3	1,961	2023-03-02	docetaxel	Its name	ClinicalTrials.gov
NCT00744497	Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-resistant Prostate Cancer	Phase 3	1,930	2014-02-06	docetaxel	Its name	ClinicalTrials.gov
NCT00312377	ZACTIMA (an Anti-EGFR / Anti-VEGF Agent) Combined With Docetaxel Compared to Docetaxel in Non-small Cell Lung Cancer	Phase 3	1,690	2011-05-24	docetaxel	Its name	ClinicalTrials.gov

1 to 10 of 2,251

See all 2,251 trials

Comparisons in its trials428

Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Biomarker Cohort vs Non-biomarker Cohort: deaths from any cause	364 of 618	3,780 of 4,661	5,279	NCT05834348	Trial comparisons
Pertuzumab + Trastuzumab + Chemotherapy vs Placebo + Trastuzumab + Chemotherapy: deaths from any cause	205 of 2,400	247 of 2,404	4,804	NCT01358877	Trial comparisons
Pertuzumab + Trastuzumab + Chemotherapy vs Placebo + Trastuzumab + Chemotherapy: serious adverse events	792 of 2,364	686 of 2,405	4,769	NCT01358877	Trial comparisons
Doxorubicin + Cyclophosphamide Followed by Docetaxel (AC -> T) vs Docetaxel + Doxorubicin and Cyclophosphamide (TAC): Local, Regional or Metastatic Relapse, or Second Primary Cancer, or Death From Any Cause (Disease-Free Survival)	356 of 1,649	352 of 1,649	3,298	NCT00312208	Trial comparisons
Doxorubicin + Cyclophosphamide Followed by Docetaxel (AC -> T) vs Docetaxel + Doxorubicin and Cyclophosphamide (TAC): Death From Any Cause (Overall Survival)	187 of 1,649	202 of 1,649	3,298	NCT00312208	Trial comparisons
Doxorubicin + Cyclophosphamide Followed by Docetaxel (AC -> T) vs Docetaxel + Doxorubicin and Cyclophosphamide (TAC): serious adverse events	331 of 1,634	520 of 1,635	3,269	NCT00312208	Trial comparisons
Arm I (Chemotherapy) vs Arm II (Chemotherapy, Trastuzumab): deaths from any cause	48 of 1,622	61 of 1,628	3,250	NCT01275677	Trial comparisons
Arm I (Chemotherapy) vs Arm II (Chemotherapy, Trastuzumab): serious adverse events	31 of 1,615	96 of 1,625	3,240	NCT01275677	Trial comparisons
AC Then T vs AC Then XT: serious adverse events	264 of 1,305	200 of 1,283	2,588	NCT00089479	Trial comparisons
TC Arm vs TAC Arm: deaths from any cause	110 of 969	88 of 965	1,934	NCT00493870	Trial comparisons

1 to 10 of 428

See all 428 comparisons in its trials

Papers from its trials1,223

The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
41653501	RESULT	1	PubMed
41615067	RESULT	1	PubMed
41324998	RESULT	1	PubMed
41202501	RESULT	1	PubMed
40069402	RESULT	1	PubMed
40043230	RESULT	1	PubMed
39703564	RESULT	1	PubMed
39018515	RESULT	1	PubMed
38926066	RESULT	1	PubMed
38429210	RESULT	2	PubMed

1 to 10 of 1,223

See all 1,223 papers from its trials

Tests in its trials3

The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.

Test	Trials naming it as an outcome	Source
Picture Naming Test	1	ConductCognition
Stroop Color-Word Test	1	ConductCognition
Verbal Fluency	1	ConductCognition

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
ClinicalTrials.gov: 2026-11-05; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
Papers the trials list, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
Tests named in the trials, as ScienceGraph matched them: 2026-11-12; ConductCognition

Sources 7

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ConductCognition's list of its testsOur own data
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this drug from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/drugs/v1/CHEMBL3545252

GET https://conductscience.org/api/drugs/v1/CHEMBL3545252/diseases?page=2

API reference For AI assistants